Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Forum
  • Discovery
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Ascelia Pharma - Presentation of Q3 2023

By HC Andersen Capital
Ascelia Pharma

Meet and ask questions CEO Magnus Corfitzen from Ascelia Pharma on 9 November at 2.30PM CET.

The topic for this event is the Q3 report and major events during the quarter. It’s been a very busy quarter for Ascelia Pharma with major news flow on the Sparkle study.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 3.11 PM 18 October 2023.

Recent videos

HCA Morgenbørs 14/04 - Markedet forsøger at løfte sig
14.04.2026, 09.25 Demant
Carasent, Audiocast, Q1'26
14.04.2026, 08.00 Carasent
Revenio’s press conference on the Visionix acquisition
13.04.2026, 13.00 Revenio Group
HCA Morgenbørs 13/04 - Ingen USA/Iran-aftale var nok ventet, men Trump's deadline er en presbold
13.04.2026, 10.28 ISS
HCA Morgenbørs 10/04 - Flade markeder og usikkerhed
10.04.2026, 09.42 Novo Nordisk
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.